Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Canagliflozin

FDA-approved product (tablet, oral), marketed as Canagliflozin, Invokana.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Canagliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Canagliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Canagliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

    NCT01787357 · start 2008-06

    Registered record
    Registry ID
    NCT01787357
    Conditions
    Healthy
    Interventions
    Canagliflozin (JNJ-28431754); Placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin (JNJ-28431754); Placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

    NCT01177163 · start 2008-05

    Registered record
    Registry ID
    NCT01177163
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo; JNJ 28431754 300 mg/placebo; JNJ 28431754 100 mg/placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-03
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo; JNJ 28431754 300 mg/placebo; JNJ 28431754 100 mg/placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

    NCT01756417 · start 2007-10

    Registered record
    Registry ID
    NCT01756417
    Conditions
    Healthy
    Interventions
    Metformin; Canagliflozin (JNJ-28431754)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-10
    Completion
    2007-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetformin; Canagliflozin (JNJ-28431754)
    PhasePhase 1
    Registry statusCompleted

  • A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

    NCT00963768 · start 2007-06

    Registered record
    Registry ID
    NCT00963768
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    JNJ 28431754; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-12
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionJNJ 28431754; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

    NCT01177150 · start 2006-11

    Registered record
    Registry ID
    NCT01177150
    Conditions
    Healthy
    Interventions
    JNJ-28431754/ Placebo; JNJ-28431754
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-04
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-28431754/ Placebo; JNJ-28431754
    PhasePhase 1
    Registry statusCompleted